[Albendazole in the treatment of strongyloidiasis. Report of 66 cases].
Albendazole, a new broad spectrum anthelmintic, has been tested in 66 adult patients infected by S. stercoralis. 77.2% cure rate was observed following 800 mg once a day for 3 consecutive days, based on repeated fecal examinations using a concentration technic (Junod) and a Baermann test, carried out during 6 to 9 months following treatment. Associated ancylostomiasis caused by N. americanus and trichuriasis were also completely cured (100%). Based on clinical side effects and laboratory investigations, the drug did not produce any significant adverse reactions.
D000328:Adult; D015766:Albendazole; D000871:Anthelmintics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013322:Strongyloidiasis / Q000188:drug therapy*
D000871:Anthelmintics; D001562:Benzimidazoles; D015766:Albendazole
L'albendazole dans le traitement de la strongyloidose. A propos de 66 observations.